Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial of FOLFOX Bevacizumab Plus Botensilimab and Balstilimab (3B-FOLFOX) in Patients With MSS Metastatic Colorectal Cancer

NCT05627635 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05627635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05627635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial of FOLFOX Bevacizumab Plus Botensilimab and Balstilimab (3B-FOLFOX) in Patients With MSS Metastatic Colorectal Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 3, 2023
Completion date
June 16, 2027
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colon adenocarcinoma, metastatic colorectal adenocarcinoma, metastatic microsatellite stable colorectal carcinoma, metastatic rectal adenocarcinoma, stage iv colon cancer ajcc v8, stage iv colorectal cancer ajcc v8, stage iv rectal cancer ajcc v8